Knight Therapeutics Inc.
GUD
Rank in Stocks
#9550
Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in... Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in Montreal, Canada in 2013, operates globally, with a strong presence across Canada and Latin America. The company's core business revolves around the development, acquisition, in-licensing, out-licensing, promotion, and distribution of a diverse portfolio encompassing pharmaceutical products, consumer health goods, and medical devices. Its extensive product catalog features treatments such as Nerlynx, prescribed for extended adjuvant and metastatic breast cancer; Tafasitamab, used for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib, targeting metastatic cholangiocarcinoma; Trelstar, addressing advanced prostate cancer and pain associated with endometriosis; Vidaza, indicated for myelodysplastic syndrome; Abraxane, for metastatic pancreatic adenocarcinoma; Halaven, for metastatic breast cancer and soft tissue sarcoma; and Lenvima, useful in differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company's offerings further include Ladevina, for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix, for metastatic prostate cancer; Karfib, for relapsed or refractory multiple myeloma; Leprid, for advanced prostate cancer; and Rembre, for chronic myeloid leukemia. For infectious diseases, it provides Ambisome and Cresemba for fungal infections, along with Impavido for leishmaniasis. Other notable products include Exelon, managing mild to moderately severe dementia; Ibsrela, for irritable bowel syndrome with constipation; Salofalk, for ulcerative colitis; Ursofalk, to treat biliary cirrhosis; Imvexxy, for moderate to severe dyspareunia; Bijuva, for moderate to severe vasomotor symptoms linked to menopause in women with intact uteri; Fibridoner, for idiopathic pulmonary fibrosis; Toliscrin DPI, addressing pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2, for severe acute or resistant chronic infections; and Tobradosa Haler, for chronic lung infections. Beyond its product-focused endeavors, Knight Therapeutics Inc. also provides financing to other life science companies and makes strategic investments in life sciences venture capital funds.
Share Price
$8.46
Last synced: 2026-11-12
Market Cap
$830.64M
Change (1 day)
-0.27%
Change (1 year)
92.95%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Knight Therapeutics Inc. (GUD)
Category
Healthcare
Operating Margin for Knight Therapeutics Inc. (GUD)
Operating Margin as of November 2026 TTM: 4.82%
According to Knight Therapeutics Inc.'s latest financial reports, its current operating margin (TTM) is 4.82%. At the end of 2025 the company had an operating margin of -0.49%.
Operating Margin history for Knight Therapeutics Inc. from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 4.82% | -1,083.67% |
| 2025 | -0.49% | -124.62% |
| 2024 | 1.99% | -326.14% |
| 2023 | -0.88% | 7.32% |
| 2022 | -0.82% | -62.56% |
| 2021 | -2.19% | 27.33% |
| 2020 | -1.72% | -105.84% |
| 2019 | 29.47% | -163.71% |
| 2018 | -46.26% | -55.15% |
| 2017 | -103.15% | -21.81% |
| 2016 | -131.92% | -87.90% |
| 2015 | -1,090.45% | -20.83% |
| 2014 | -1,377.36% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -95.97% |
DE
|
|
| 19.68% | -95.92% |
DE
|
|
| 13.26% | -97.25% |
JP
|
|
| 17.08% | -96.46% |
CH
|
|
| 14.92% | -96.90% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Knight Therapeutics Inc.'s operating margin
What is Knight Therapeutics Inc.'s operating margin?
Knight Therapeutics Inc.'s operating margin is 4.82%, as of Nov 2026.
What was Knight Therapeutics Inc.'s operating margin in 2025?
In 2025, Knight Therapeutics Inc.'s operating margin was -0.49%, compared with 1.99% in 2024.
How has Knight Therapeutics Inc.'s operating margin changed since 2020?
From 2020 to 2025, Knight Therapeutics Inc.'s operating margin was highest in 2024 (1.99%) and lowest in 2021 (-2.19%).
How does Knight Therapeutics Inc.'s operating margin compare with similar companies?
Knight Therapeutics Inc.'s operating margin (4.82%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.